{{Rsnum
|rsid=3972219
|Gene=GNA13
|Chromosome=17
|position=65022415
|Orientation=plus
|GMAF=0.03352
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=GNA13
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 81.5 | 18.5 | 0.0
| HCB | 100.0 | 0.0 | 0.0
| JPT | 97.8 | 2.2 | 0.0
| YRI | 100.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 100.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs3972219
|Name_s=
|Gene_s=GNA13
|Feature=
|Evidence=PubMed ID:19910028
|Annotation=in a GWAS of subjects of African ancestry(African American plus African Caribbean), this SNP was found to be significantly associated with Asthma, but its minor allele frequency was less than 1% in this population and replication attempts were not performed. Risk or phenotype-associated allele: G. Phenotype: increased risk for asthma. Study size/population/ethnicity: 1) 935 African American asthmatic cases and control subjects from the Baltimore-Washington area (2) 929 African Caribbean asthmatic subjects and their family members from Barbados . Significance metric(s): combined p = 7.11 x 10(-6). Type of association: CO; GN.
|Drugs=
|Drug Classes=
|Diseases=Asthma
|Curation Level=Curated
|PharmGKB Accession ID=PA165111742
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}